Anixa Biosciences Reports Reduced Net Loss, Strong Cash Runway, and Positive Clinical Progress for Breast Cancer Vaccine and CAR-T Therapy

summarizeSummary

Anixa Biosciences reported a reduced net loss and improved EPS for the quarter, bolstered by a successful $1.625 million ATM offering and a projected cash runway of over 12 months. The company also announced positive Phase 1 results for its breast cancer vaccine and encouraging anecdotal efficacy from its CAR-T ovarian cancer therapy.

check_boxKey Events · Earnings and Guidance · ANIX

• Reduced Net Loss and Improved EPS

  For the three months ended January 31, 2026, the company reported a net loss of $2.585 million, an improvement from a net loss of $3.213 million in the prior year's quarter. Basic and diluted EPS improved to $(0.08) from $(0.10).

• Strong Cash Position and Runway

  Anixa Biosciences holds $14.202 million in cash, cash equivalents, and short-term investments as of January 31, 2026. Management believes these funds are sufficient to operate the business for 'significantly longer than 12 months' from the report date of March 9, 2026.

• Successful At-The-Market (ATM) Offering

  The company raised $1.625 million, net of expenses, by selling 429,328 shares of common stock through its ATM equity program during the quarter. Approximately $98 million remains available under this program for future capital raises.

• Positive Phase 1 Results for Breast Cancer Vaccine

  The Phase 1 clinical trial for the breast cancer vaccine met all primary endpoints, demonstrating safety, tolerability, and protocol-defined immune responses in 74% of subjects. The company is now preparing to initiate a Phase 2 clinical trial.

auto_awesomeAnalysis · ANIX · Life Sciences

This quarterly report provides a comprehensive update on Anixa Biosciences' financial health and critical clinical pipeline. The reduction in net loss and improved EPS, coupled with a successful ATM offering and management's projection of a cash runway extending "significantly longer than 12 months," significantly de-risks the company's near-term financial outlook. The positive Phase 1 results for the breast cancer vaccine, meeting all primary endpoints and showing strong immune response and safety, are a major step forward, paving the way for a Phase 2 trial. Additionally, the anecdotal signs of efficacy and extended survival in ovarian cancer patients treated with the CAR-T therapy are encouraging, especially given the limited options for this patient population. These clinical advancements, combined with a strengthened financial position, are highly material for a clinical-stage biotech company.